Navigation Links
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
Date:5/26/2011

MOUNTAIN VIEW, Calif., May 26, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a debilitating neurological disorder. Common symptoms of migraine include recurrent headaches, nausea, phonophobia (sensitivity to sound) and photophobia (sensitivity to light).

"This NDA submission marks a major corporate milestone for MAP Pharmaceuticals and brings us one step closer to our goal of providing the underserved migraine patient population with a potential new treatment option," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Our comprehensive development program evaluated LEVADEX in approximately 1,000 patients for up to one year, treating nearly 10,000 migraines. If approved by the FDA, LEVADEX could potentially provide a new treatment option for migraine sufferers, including the millions of patients whose migraines are not well treated today."

The 505(b)(2) NDA submission is based on a comprehensive development program for LEVADEX, and includes efficacy and safety data from the Phase 3 FREEDOM-301 clinical trial that has been presented at scientific conferences and was recently published in Headache: The Journal of Head and Face Pain. In the FREEDOM-301 trial, patients self-administered LEVADEX at home using the Company's proprietary TEMPO® inhaler. LEVADEX contains a novel formulation of dihydroergotamine (DHE).  Patients taking LEVADEX in this pivotal trial had statistically significant improvement at two hours compared to patients on placebo for all four c
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Watson Acquires Specifar Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
3. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
4. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
5. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
6. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
7. Vanda Pharmaceuticals Reports First Quarter 2011 Results
8. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
9. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed ... developer, and marketer of over-the-counter (OTC) medicinal and ... research opinion on the company based on low ... , Non-Prescription, All Natural Product to Treat ... Product Outperforms #1 Prescription Competitor , Currently ...
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... May 23, 2013 On April 19th ... to supermarkets to search for the growing antibiotic resistant ... Results from a year long study were released late ... foods, specifically meats, over previous years. For those suffering ... growth of antibiotic resistant bacteria in food, may eventually ...
(Date:5/23/2013)... SOUTH EASTON, Mass. , May 23, 2013 /PRNewswire/ ... "Company") today announced that the Company will host a ... and to provide a business update. The teleconference information ... 2013 Time: 11:00 a.m. Eastern Daylight Time (EDT) ... Canada ); (302) 607-2001 (Int,l) Passcode: VS22823 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... somehow survived where other traditional marketing tools and old ... must face harsher realities once again, all to ensure ... Web sites are simply doomed. While billions of Web ... clash into the billions of surfing customers and simply ...
... Ted Kanavas, R-Brookfield, called on the Legislature and the ... Development Fund. , ,The fund would use existing information ... Administration and segregate a portion of the funds for ... would not flow into this fund. , ,This fund ...
... Corporation and First Data Corporation jointly ... provides for the purchase of substantially all of the ... approximately $610 million in cash. As the majority shareholder ... million and NYCE will become a Metavante subsidiary. , ...
Cached Biology Technology:The mysteries and the future of Web sites 2The mysteries and the future of Web sites 3The mysteries and the future of Web sites 4Metavante and First Data to buy PIN-debit company NYCE 2
(Date:5/23/2013)... medics have succeeded in treating cerebral palsy with autologous ... damage, a 2.5 year old boy had been in ... survival. Just two months after treatment with the cord ... the following months, the child learned to speak simple ... from a Korean study, dispel the long-held doubts about ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
(Date:5/23/2013)... In an age when microbial pathogens are growing ... down infection, a team of Wisconsin scientists has synthesized ... the bacteria that cause staph infections. , Writing online ... , a group led by University of Wisconsin-Madison chemistry ... the "quorum sensing" behavior of Staphylococcus aureus , ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2
... It is estimated that 38 million people worldwide are ... are added each year. For scientists to design treatment ... essential to learn more about how the virus mutates ... by University of Victoria biomedical engineer Stephanie Willerth has ...
... III efficacy data from the GeparQuinto study, a head-to-head ... chemotherapy for patients with early breast cancer, at the ... Dec. 8-12. "We had a primary goal ... trastuzumab, with the new combination of chemotherapy and lapatinib," ...
... Alexandria, VA America has made great strides in recent ... to other, low or non-carbon energy sources. Meanwhile, carbon emissions ... looks at this disparity and asks the difficult questions about ... is imported from "cleaner" countries and the emissions are produced ...
Cached Biology News:UVic biomedical engineer 'outsmarts' HIV 2Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer 2